BNTC Gene Therapy Penny Stock at All Time Low

BNTC Benitec Biopharma Inc is a development-stage biotechnology company which focuses on the development of novel genetic medicines.
The company develops DNA-directed RNA interference based therapeutics.

BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc. and Morgan Stanley have stakes in it.

On 2/17/2022 P. Trucchio from HC Wainwright brokerage Initiated Coverage for BNTC with a Buy rating and a price target of $10.00.

The price of the stock can easily double in my opinion.